SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets warning letter from USFDA for Somerset facility

14 Jun 2021 Evaluate

Lupin has received a warning letter from the United States Food and Drug Administration (USFDA) for the company’s Somerset, New Jersey facility. The USFDA had inspected the Lupin Somerset site from September 10, 2020 to November 5, 2020. The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.


Lupin Share Price

2484.70 8.60 (0.35%)
06-Jul-2026 12:13 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1906.05
Dr. Reddys Labs. 1359.00
Cipla 1460.55
Zydus Lifesciences 1146.95
Lupin 2484.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: